Nuveen’s Neuropace NPCE Stock Holding History

Nuveen’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.17M	Sell	89,287 -3,497	-4%	-$52.5K	﹤0.01%	2505
2025 Q4	$1.43M	Buy	92,784 +61,550	+197%	+$823K	﹤0.01%	2437
2025 Q3	$322K	Hold	31,234	–	–	﹤0.01%	3039
2025 Q2	$348K	Buy	31,234 +12,814	+70%	+$160K	﹤0.01%	2990
2025 Q1	$226K	Hold	18,420	–	–	﹤0.01%	3105
2024 Q4	$206K	Hold	18,420	–	–	﹤0.01%	3203
2024 Q3	$128K	Hold	18,420	–	–	﹤0.01%	3289
2024 Q2	$139K	Buy	+18,420	New	+$186K	﹤0.01%	3281
2022 Q2	–	Sell	-17,850	Closed	-$150K	–	3413
2022 Q1	$150K	Hold	17,850	–	–	﹤0.01%	3222
2021 Q4	$162K	Hold	17,850	–	–	﹤0.01%	3256
2021 Q3	$311K	Buy	17,850 +6,842	+62%	+$144K	﹤0.01%	3246
2021 Q2	$262K	Buy	+11,008	New	+$255K	﹤0.01%	3229

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Nuveen's NPCE Position: Q1 2026 in Review

Nuveen reduced its Neuropace (NPCE) stake by 3.8% in Q1 2026, selling an estimated $52.5K and leaving 89,287 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2505.

Nuveen first reported a position in NPCE in Q2 2021 and has held it in 12 quarters since. The position peaked at $1.43M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

Nuveen held 89,287 shares of Neuropace worth $1.17M as of Q1 2026.
Nuveen sold 3,497 Neuropace shares in Q1 2026, an estimated $52.5K.
Neuropace made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2505 holding.
Nuveen first reported a position in Neuropace in Q2 2021 and has held it in 12 quarters since.
Nuveen's Neuropace position peaked at $1.43M in Q4 2025.
113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.